FinanceRecent
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
Economic Times — Markets✓
Original Reporting
AI EXECUTIVE SUMMARY
Aurobindo Pharma's shares rose more than 3% after its subsidiary Lannett Company introduced a generic version of the Advair Diskus inhaler in the United States. The product, offered in two dosage strengths, is the first commercial offering from Aurobindo's inhalation pipeline. The stock has gained about 41% year‑to‑date in 2026.
WHY IT MATTERS
The launch adds a new revenue source and demonstrates progress in Aurobindo's inhalation drug development, influencing its market valuation.
Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindo’s inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.
This story was originally reported by Economic Times — Markets. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
ALSO REPORTED BY OTHER SOURCES (2)
Rosenblatt reiterates Autodesk stock rating on strong Q2 results
Here’s what’s worth streaming in September 2026 on Netflix, Hulu, HBO Max and more
Community Sentiment & Coverage Reliability
Crowd-sourced evaluation based on verified reader feedback
Rate Coverage Tone:
No reader evaluations recorded yet — be the first to rate the coverage tone above!
Quick Story Reactions:
Community Discussion (0)
Join the Community Discussion
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.